Bionics is a compound word of Biology and Electronics, and it is known as a technology for replacing damaged tissues or body parts with functional prosthetics.
Bionics is a representative convergence research field that requires original technology in various fields from basic science to applied research, such as mechanical engineering, electrical/electronic engineering, biology, biomedical engineering, materials engineering, and medicine.
Bionics Research Center is developing digital healthcare technology using bi-directional (diagnosis + treatment) bio-interface and AI/robot technology to overcome various chronic/rare/intractable disorders.
The wide spectrum of research fields demands an appropriately diverse group of scientists with expertise in fields such as material/device engineering, polymer chemistry, biology, chemistry, pharmaceutics, and immunology. The CBM fosters a highly collaborative environment, in which researchers aim to develop innovative biomedical core technology geared towards tackling concerns that stem from an aging society, such as cancer and diseases of the cardiovascular and musculoskeletal systems.
Numerous advances made in the scientific and medical fields have pushed up the average life expectancy close to 70 years old. Accordingly, an emphasis on the quality of life has been made and brought to the forefront by experts spanning various fields. At the Center for Biomaterials (CBM), we strive to improve the quality of life through the concept of personalized medicine. We seek pivotal strategies for the regeneration or replacement of damaged and malfunctioning body tissues using a multitude of methods, not limited to the following: 1) Tissue engineering and stem cells, 2) Biocompatible and biofunctional biomaterials, 3) Quantitative nano-diagnostic technology, 4) Diagnostic and clinical drug-delivery systems, and 5) Cryo system-based biomimetics.
The wide spectrum of research fields demands an appropriately diverse group of scientists with expertise in fields such as material/device engineering, polymer chemistry, biology, chemistry, pharmaceutics, and immunology. The CBM fosters a highly collaborative environment, in which researchers aim to develop innovative biomedical core technology geared towards tackling concerns that stem from an aging society, such as cancer and diseases of the cardiovascular and musculoskeletal systems.
Numerous advances made in the scientific and medical fields have pushed up the average life expectancy close to 70 years old. Accordingly, an emphasis on the quality of life has been made and brought to the forefront by experts spanning various fields. At the Center for Biomaterials (CBM), we strive to improve the quality of life through the concept of personalized medicine. We seek pivotal strategies for the regeneration or replacement of damaged and malfunctioning body tissues using a multitude of methods, not limited to the following: 1) Tissue engineering and stem cells, 2) Biocompatible and biofunctional biomaterials, 3) Quantitative nano-diagnostic technology, 4) Diagnostic and clinical drug-delivery systems, and 5) Cryo system-based biomimetics.
The Medicinal Materials Research Center develops novel pharmaceutical materials for the treatment of incurable diseases. Our research interests are i) development of cancer immunotherapeutics, ii) development of tumor immune microenvironment reprogramming technology, and iii) development of precision cancer immunotherapy technology. Simultaneously, we strive to realize precision medicine (prevention, diagnosis, and treatment) for the treatment of incurable diseases through the development of patient-specific treatment technology based on ‘theragnosis’ technology and immune fusion technology.
The Medicinal Materials Research Center develops novel pharmaceutical materials for the treatment of incurable diseases. Our research interests are i) development of cancer immunotherapeutics, ii) development of tumor immune microenvironment reprogramming technology, and iii) development of precision cancer immunotherapy technology. Simultaneously, we strive to realize precision medicine (prevention, diagnosis, and treatment) for the treatment of incurable diseases through the development of patient-specific treatment technology based on ‘theragnosis’ technology and immune fusion technology.
While the advent of the 4th industrial revolution pushed the frontiers of science to generate remarkable scientific progress, the task of overcoming challenges concerning low birthrates, ageing, new infectious diseases, and rare diseases still remain. The Advanced Biomolecular Recognition Research Center is conducting research to understand the mechanisms of disease at a molecular level and to discover the mode of action of new drugs that can be applied to the diagnosis and treatment of diseases. Furthermore, by integrating nanotechnology, IT, and artificial intelligence, we are developing sensor systems targeting biomolecular markers that can be used in a clinical setting. Through cutting edge technologies introduced with the 4th industrial revolution, we pledge to lead the innovation of new drugs, early-stage disease diagnoses, and smart healthcare for all.
While the advent of the 4th industrial revolution pushed the frontiers of science to generate remarkable scientific progress, the task of overcoming challenges concerning low birthrates, ageing, new infectious diseases, and rare diseases still remain. The Advanced Biomolecular Recognition Research Center is conducting research to understand the mechanisms of disease at a molecular level and to discover the mode of action of new drugs that can be applied to the diagnosis and treatment of diseases. Furthermore, by integrating nanotechnology, IT, and artificial intelligence, we are developing sensor systems targeting biomolecular markers that can be used in a clinical setting. Through cutting edge technologies introduced with the 4th industrial revolution, we pledge to lead the innovation of new drugs, early-stage disease diagnoses, and smart healthcare for all.
Intractable diseases are generally difficult to diagnose early and there are often no effective treatments, so the treatment success rate of patients is low. The Chemical and Biological integrative Research Center aims to develop cutting-edge diagnostic and treatment technologies that can accurately diagnose incurable diseases, including cancer, and implement patient-tailored treatments through multidisciplinary integrative researches in medical engineering and pharmaceutical sciences. This research center aims to secure future medical technologies for global competitiveness and develop domestic research capabilities to a global level by discovering novel bio-nano materials necessary for the development of integrative technologies of molecular imaging and nanomedicine and performing innovative drug discovery researches.
Intractable diseases are generally difficult to diagnose early and there are often no effective treatments, so the treatment success rate of patients is low. The Chemical and Biological integrative Research Center aims to develop cutting-edge diagnostic and treatment technologies that can accurately diagnose incurable diseases, including cancer, and implement patient-tailored treatments through multidisciplinary integrative researches in medical engineering and pharmaceutical sciences. This research center aims to secure future medical technologies for global competitiveness and develop domestic research capabilities to a global level by discovering novel bio-nano materials necessary for the development of integrative technologies of molecular imaging and nanomedicine and performing innovative drug discovery researches.
The Center for “Complex Adaptive Therapeutic Strategy for Cancer” aims to develop novel strategies for awakening the intrinsic immunity against tumor by overcoming the activation energy threshold of the immuno-suppressive tumor microenvironment.
The Center for “Complex Adaptive Therapeutic Strategy for Cancer” aims to develop novel strategies for awakening the intrinsic immunity against tumor by overcoming the activation energy threshold of the immuno-suppressive tumor microenvironment.